#1 Clinical Trials Search in Europe

Nemvaleukin Alfa

Nemvaleukin Alfa is an innovative drug currently being studied in clinical trials for the treatment of advanced cancers, including head and neck squamous cell carcinoma, cutaneous melanoma, and mucosal melanoma. These trials aim to evaluate the drug’s effectiveness, safety, and potential benefits when used alone or in combination with other cancer treatments. The ongoing research provides hope for patients with these challenging cancers and may lead to new treatment options in the future.

Table of Contents

What is Nemvaleukin Alfa?

Nemvaleukin alfa, also known as ALKS 4230, is a new drug being studied for the treatment of various types of cancer[1][2]. It is designed to boost the body’s immune system to fight cancer cells more effectively. This type of treatment is called immunotherapy, which is a cutting-edge approach in cancer treatment that helps your own body’s defenses to recognize and attack cancer cells.

What Conditions Does Nemvaleukin Alfa Treat?

Nemvaleukin alfa is being studied for the treatment of several types of cancer, including:

  • Head and Neck Squamous Cell Carcinoma (HNSCC): This is a type of cancer that starts in the cells that line the mouth, nose, and throat[1].
  • Cutaneous Melanoma: This is the most common type of skin cancer that develops from the pigment-producing cells (melanocytes) in the skin[2].
  • Mucosal Melanoma: This is a rare type of melanoma that occurs in the moist, inner lining of some organs of the body, such as the nose, mouth, or genitals[2].

How Does Nemvaleukin Alfa Work?

Nemvaleukin alfa works by stimulating the immune system, particularly a type of white blood cell called T cells. These T cells are crucial in identifying and destroying cancer cells. By enhancing the activity of these cells, nemvaleukin alfa helps the body’s natural defenses to fight cancer more effectively[1][2].

How is Nemvaleukin Alfa Administered?

Nemvaleukin alfa can be administered in different ways, depending on the specific clinical trial and treatment plan:

  • Intravenous (IV) infusion: The drug is given directly into a vein. This can be done daily for 5 consecutive days in a 3-week cycle, or less frequently (twice every 21 days)[1][2].
  • Subcutaneous injection: The drug is injected under the skin every 7 days[2].

In some cases, nemvaleukin alfa is used in combination with another drug called pembrolizumab (also known as Keytruda), which is also an immunotherapy drug[1][2].

Current Clinical Trials

Nemvaleukin alfa is currently being studied in several clinical trials:

  1. ARTISTRY-6 Study: This trial is studying nemvaleukin alfa in patients with advanced cutaneous or mucosal melanoma. It’s looking at how well the drug works on its own and in combination with pembrolizumab[2].
  2. Head and Neck Cancer Study: This trial is investigating the use of nemvaleukin alfa in combination with pembrolizumab in patients with advanced or recurrent head and neck squamous cell cancer who have previously received immunotherapy treatment[1].

How Effective is Nemvaleukin Alfa?

The effectiveness of nemvaleukin alfa is still being studied in clinical trials. Researchers are looking at several measures to determine how well the drug works:

  • Overall Response Rate (ORR): This measures the percentage of patients whose cancer shrinks or disappears after treatment[1][2].
  • Duration of Response (DOR): This measures how long the cancer remains controlled after it has responded to treatment[1][2].
  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse[1][2].
  • Overall Survival (OS): This measures how long patients live after starting treatment[1].

The results of these trials will help determine how effective nemvaleukin alfa is in treating various types of cancer.

Potential Side Effects

As with any medical treatment, nemvaleukin alfa may cause side effects. The clinical trials are closely monitoring patients for any adverse reactions. These may include:

  • Treatment-emergent adverse events (TEAEs): These are any unfavorable and unintended signs, symptoms, or diseases that occur during the treatment period[1][2].
  • Serious adverse events (SAEs): These are more severe side effects that may require medical intervention[1].

It’s important to note that not all patients will experience side effects, and the severity can vary from person to person. The researchers are carefully monitoring these effects to ensure patient safety and to better understand the drug’s overall risk-benefit profile.

Aspect Details
Drug Name Nemvaleukin Alfa (also known as ALKS 4230)
Cancer Types Studied Head and neck squamous cell carcinoma, Cutaneous melanoma, Mucosal melanoma
Administration Methods Intravenous (IV) infusion, Subcutaneous injection
Combination Therapy Sometimes used with Pembrolizumab
Primary Outcomes Measured Overall Response Rate (ORR)
Secondary Outcomes Measured Duration of Response (DOR), Progression-Free Survival (PFS), Disease Control Rate (DCR), Time to Response (TTR), Safety and Tolerability
Trial Durations Up to 2 years from the first dose
Key Goals Evaluate effectiveness, safety, and potential benefits of Nemvaleukin Alfa alone or in combination with other treatments

FAQ

  • What is Nemvaleukin Alfa? Nemvaleukin Alfa is a new drug being tested in clinical trials for treating advanced cancers. It's designed to boost the immune system's ability to fight cancer cells.
  • What types of cancer is Nemvaleukin Alfa being tested for? The clinical trials are focusing on advanced head and neck squamous cell carcinoma, cutaneous melanoma (skin cancer), and mucosal melanoma (a rare type of melanoma).
  • How is Nemvaleukin Alfa given to patients? Nemvaleukin Alfa can be given in different ways, depending on the trial. It may be administered as an intravenous (IV) infusion or as a subcutaneous injection under the skin.
  • Is Nemvaleukin Alfa used alone or with other drugs? In some trials, Nemvaleukin Alfa is used alone, while in others, it's combined with another drug called Pembrolizumab. The combination approach is being tested to see if it's more effective than using either drug on its own.
  • What are researchers looking for in these clinical trials? Researchers are primarily interested in how well Nemvaleukin Alfa works against cancer (its effectiveness), how safe it is to use, and how long its effects last. They're measuring things like overall response rate, duration of response, and progression-free survival, as well as monitoring for any side effects.

Ongoing Clinical Trials on Nemvaleukin Alfa

  • Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +4

  • Study on Nemvaleukin Alfa and Pembrolizumab for Patients with Advanced Skin or Mucosal Melanoma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy Spain

Glossary

  • Nemvaleukin Alfa: A new drug being tested in clinical trials for treating advanced cancers by enhancing the immune system's ability to fight cancer cells.
  • Pembrolizumab: An existing cancer drug that works by helping the immune system detect and fight cancer cells. It's sometimes used in combination with Nemvaleukin Alfa in clinical trials.
  • Squamous Cell Carcinoma: A type of skin cancer that develops in the squamous cells, which make up the middle and outer layers of the skin.
  • Cutaneous Melanoma: The most common type of melanoma, a serious form of skin cancer that develops in the cells that produce melanin, the pigment that gives skin its color.
  • Mucosal Melanoma: A rare type of melanoma that occurs in the mucous membranes of the body, such as those lining the nasal passages, mouth, or genital areas.
  • Intravenous (IV) Infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Disease Control Rate (DCR): The percentage of patients who have a complete response, partial response, or stable disease as a result of treatment.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.
  • Stable Disease (SD): Cancer that is neither decreasing nor increasing in extent or severity.
  • Progressive Disease (PD): Cancer that is growing, spreading, or getting worse.

References